Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Summary
Here's a polished version of the text: "This project involves patients with high-expression LRRC15 malignant tumors who are either clinically suspected of or diagnosed with pancreatic cancer, breast cancer, lung cancer, ovarian cancer, head and neck tumors, colorectal cancer, melanoma, etc., as well as healthy volunteers. Using a targeted LRRC15-specific SPECT imaging agent, SPECT/CT imaging is performed to achieve the following objectives: For malignant tumor patients: To support disease diagnosis and staging. Diagnostic performance will be evaluated against the gold standard of pathological diagnosis, clarifying the presence or absence of lesions and determining their location and nature. To enable accurate staging and assess tumor burden by comparison with \[18F\]FDG PET/CT, thereby aiding in the determination of treatment plans. For healthy volunteers: To conduct pharmacokinetic analysis, elucidating the distribution, metabolism, and safety profile of the agent in the body."
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1
Start Date
2025-03-01
Completion Date
2026-02-28
Last Updated
2026-06-16
Healthy Volunteers
Yes
Conditions
Interventions
Specific SPECT imaging agents targeting LRRC15
This project utilizes LRRC15-specific targeted SPECT radiotracers to perform SPECT/CT imaging on healthy volunteers and patients with clinically suspected or confirmed malignancies characterized by high LRRC15 expression-including pancreatic cancer, breast cancer, lung cancer, sarcoma, head and neck tumors, glioblastoma, colorectal cancer, and melanoma.
Locations (1)
Wuhan Union Hospital, China
Wuhan, Hubei, China